Levophencynonate

Drug Profile

Levophencynonate

Alternative Names: (L)-phencynonate; (L)-phencynonate hydrochloride; L-hydrochloric acid phencynonate; L-LPC; L-phencynonate; L-phencynonate hydrochloride; Levo phencynonate hydrochloride; Levophencynonate hydrochloric; LH tablet

Latest Information Update: 04 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Academy of Military Medical Sciences
  • Developer Sihuan Pharmaceutical Holdings Group
  • Class Antiemetics; Aza compounds; Glycolates
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Vertigo

Most Recent Events

  • 04 Apr 2017 Preregistration for Vertigo in China (PO) before April 2017 (Sihuan Pharmaceutical pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top